CD170 Antibodies: Blocking Myeloid-Derived Suppressor Cell-Mediated Tumor Immune Escape

1. Concept
CD170 (also known as Siglec-E in mice), a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, is a key inhibitory receptor expressed on myeloid-derived suppressor cells (MDSCs). Abnormal sialylation of tumor cell surface glycans— a hallmark of cancer—enables binding to CD170 via its extracellular domain, triggering intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) to transmit immunosuppressive signals. In the tumor microenvironment (TME), highly sialylated MDSCs enhance their immunosuppressive capacity through CD170 ligation, forming a critical network that mediates tumor immune escape. CD170 antibodies, developed by ANT BIO PTE. LTD., enable precise detection and functional blocking of this receptor, supporting research into novel cancer immunotherapy strategies.

2. Research Frontiers
Cutting-edge research on CD170 has uncovered its pivotal role in tumor immunity, driving innovations in targeted immunotherapy:
Tumor-Specific Expression and Function: CD170 is highly expressed on MDSCs from lung cancer patients and mouse tumor models, with expression levels closely correlating to MDSC-mediated T cell suppression. Myeloid cell-specific CD170 knockout significantly delays tumor growth and enhances CD8+ T cell infiltration/activation in tumors—validating CD170 as a key mediator of immune escape.
Molecular Mechanisms of Immunosuppression: CD170 activation upregulates chemokine CCL2 expression, a critical downstream effector that reinforces the immunosuppressive TME. Neutralizing CCL2 reverses CD170-mediated suppression and prolongs survival in tumor-bearing animals. Blocking CD170-ligand interactions or reducing cell surface sialylation also attenuates MDSC-induced T cell dysfunction.
Therapeutic Potential: Preclinical studies confirm that CD170 antibody blockade or enzymatic removal of sialic acids restores anti-tumor T cell function. Mechanisms are conserved across species—CD170 blockade reduces immunosuppression in human monocyte-derived MDSCs—supporting clinical translation.
Synergy with Immune Checkpoints: CD170 may synergize with PD-1/CTLA-4 pathways, forming a complex inhibitory network in the TME. Preliminary evidence suggests CD170 blockade enhances the efficacy of existing checkpoint inhibitors, offering a strategy to overcome immunotherapy resistance.

3. Research Significance
CD170 research holds profound implications for cancer immunology and therapeutic development:
Unraveling Immune Escape Mechanisms: It reveals the role of sialylation-CD170 crosstalk in MDSC-mediated suppression, expanding understanding of TME biology and immunosuppressive networks.
Novel Therapeutic Target Validation: CD170’s tumor-specific upregulation on MDSCs makes it a safe, precise target for immunotherapy—addressing the unmet need to reverse MDSC-induced immune dysfunction.
Combination Therapy Innovation: CD170 blockade synergizes with existing immunotherapies, providing a pathway to improve treatment responses in patients resistant to checkpoint inhibitors.
Research Tool Value: High-quality CD170 antibodies enable accurate identification of MDSCs and analysis of their immunosuppressive functions, advancing studies in tumor immunity, inflammation, and infection.

4. Related Mechanisms, Research Methods, and Product Applications
Related Mechanisms
CD170 mediates tumor immune escape through conserved molecular pathways:
Sialic Acid-Ligand Binding: CD170 binds sialylated glycans on tumor cells or MDSCs, activating ITIM signaling to suppress T cell activation and proliferation.
CCL2-Mediated Immunosuppression: CD170 activation upregulates CCL2 secretion, which recruits additional immunosuppressive cells and reinforces the inhibitory TME.
MDSC Functional Enhancement: CD170 ligation enhances MDSC’s ability to produce reactive oxygen species (ROS), arginase-1, and interleukin-10—further suppressing anti-tumor immunity.

Research Methods
CD170 antibodies support core research techniques in tumor immunology:
Expression Analysis: Flow cytometry and immunofluorescence to detect CD170 on MDSCs, macrophages, and neutrophils in human samples and mouse models.
Functional Assays: T cell proliferation/suppression assays to evaluate the impact of CD170 blockade on MDSC-mediated immune inhibition.
Signaling Pathway Studies: Western blot and qPCR to investigate CD170-induced CCL2 upregulation and ITIM signaling activation.
In Vivo Efficacy Assessment: Tumor-bearing mouse models to evaluate tumor growth, T cell infiltration, and survival after CD170 antibody treatment—alone or in combination with checkpoint inhibitors.

Product Applications by ANT BIO PTE. LTD.
ANT BIO PTE. LTD., via its sub-brand STARTER (specializing in high-performance antibodies), offers a curated portfolio of CD170 antibodies with exceptional specificity, affinity, and batch consistency. These products are rigorously validated for flow cytometry and functional assays, enabling diverse research applications:
Tumor Immune Microenvironment Research: Analysis of CD170+ MDSC infiltration and immunosuppressive functions in tumors.
Myeloid Cell Function Studies: Investigation of CD170’s role in macrophage/neutrophil activation, migration, and immune regulation.
Inflammation and Immune Tolerance Research: Exploration of CD170-mediated negative regulation of inflammation and immune tolerance mechanisms.
Infection Immunology: Studies on CD170’s role in modulating host immune responses to pathogens.

5. Brand Mission
At ANT BIO PTE. LTD., our mission is to empower global innovative pharmaceutical companies, research institutions, and life science researchers with high-quality, high-value biological reagents and comprehensive solutions. Leveraging state-of-the-art technology platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development systems (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—we strive to accelerate scientific discovery and translational research. Our sub-brands (Absin for general reagents and kits, STARTER for antibodies, and UA for recombinant proteins) synergize to address diverse research needs, contributing to breakthroughs in oncology, immunology, and inflammatory biology. With certifications including EU 98/79/EC, ISO9001, and ISO13485, we uphold the highest standards of quality and reliability to support our mission of advancing human health through science.

6. Related Product List

S0B5084	Alexa Fluor® 647 Rat Anti-Mouse CD170 Antibody (S-R691)	Host : Rat Conjugation : Alexa Fluor® 647
S0B5103	Rat Anti-Mouse CD170 Antibody (S-R691)	Host : Rat Conjugation : Unconjugated

7. AI Disclaimer
This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
 
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.